Its mechanism of action involves the removal of H3K27me3 from NF-κB inflammatory gene promoters in Mфs, thereby contributing to adverse vascular remodeling, aortic dilation, and AAA progression. The gene discussed is NFKB1; the disease is triple-A syndrome.